{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments.\n\nCR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions.\n\nPD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions.\n\nSD (stable disease) = small changes that do not meet above criteria.","groups":[{"description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","id":"OG000","title":"Pemetrexed"}],"paramType":"NUMBER","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"baseline, up to 18 weeks","title":"Overall Tumor Response","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}